Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check7 days agoChange DetectedLakefront Biotherapeutics NV was added as a collaborator and Galapagos NV was removed from the study's Collaborators and Investigators list.SummaryDifference0.0%

- Check14 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a small platform update.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe page’s site revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check43 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check71 days agoChange Detected- Revision: v3.5.0 has been added, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check86 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.